U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07335406) titled 'Registry for the Management of Helicobacter Pylori Infection in Shandong Province' on Jan. 05.
Brief Summary: Helicobacter pylori infection is a common global gastrointestinal infectious disease, affecting approximately 43.1% of the world's population. Eradicating H. pylori is crucial for reducing the risk of developing conditions such as gastritis, peptic ulcer disease, and gastric cancer. Currently, 14-day high-dose dual therapy containing amoxicillin and bismuth-containing quadruple therapy are the guideline-recommended first-line treatment regimens for H. pylori eradication. Treatment options for H. pylori vary considerably, wit...